{"filing":{"accession_number":"0001932393-26-000039","cik":"0001932393","ticker":"GEHC","company_name":"GE HealthCare Technologies Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"gehc-20260721.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1932393/000193239326000039/gehc-20260721.htm"},"events":[{"id":20092,"run_id":18088,"accession_number":"0001932393-26-000039","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"GE HealthCare Technologies disclosed preliminary unaudited Q2 2026 financial results, reporting revenue growth of 5.7% year-over-year and organic revenue growth of 3.5%, with adjusted EPS performance ahead of prior expectations.","company_name":"GE HealthCare Technologies Inc.","ticker":"GEHC","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19360,"accession_number":"0001932393-26-000039","item_number":"2.02","item_title":"Results of Operation and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses preliminary unaudited Q2 2026 financial results including revenue growth of 5.7% year-over-year and organic revenue growth of 3.5%, along with adjusted EPS performance ahead of prior expectations. While the press release also announces a CFO transition (Saccaro stepping down, Newcomb appointed as interim CFO), the Item 2.02 disclosure centers on the financial results announcement, which is the primary content of the earnings release furnished as Exhibit 99. The CFO transition is secondary context within the same release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:21:40.171515+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":20093,"run_id":18088,"accession_number":"0001932393-26-000039","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"James K. Saccaro, Chief Financial Officer, resigned effective August 14, 2026, to pursue a role outside the medical technology industry. George Newcomb was appointed as interim CFO.","company_name":"GE HealthCare Technologies Inc.","ticker":"GEHC","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19361,"accession_number":"0001932393-26-000039","item_number":"5.02","item_title":"Departure of Directors or Certain Officers","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"James K. Saccaro, Chief Financial Officer, is resigning effective August 14, 2026, to pursue a role outside the medical technology industry. While the filing also discloses the appointment of George Newcomb as interim CFO, the principal disclosed action centers on Saccaro's departure—a named executive officer leaving his position after three years. The CFO role is material to investor assessment of the company's financial leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:21:40.171515+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19360,"accession_number":"0001932393-26-000039","item_number":"2.02","item_title":"Results of Operation and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses preliminary unaudited Q2 2026 financial results including revenue growth of 5.7% year-over-year and organic revenue growth of 3.5%, along with adjusted EPS performance ahead of prior expectations. While the press release also announces a CFO transition (Saccaro stepping down, Newcomb appointed as interim CFO), the Item 2.02 disclosure centers on the financial results announcement, which is the primary content of the earnings release furnished as Exhibit 99. The CFO transition is secondary context within the same release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:21:40.171515+00:00","company_name":"GE HealthCare Technologies Inc.","ticker":"GEHC","filing_date":"2026-07-23"},{"id":19361,"accession_number":"0001932393-26-000039","item_number":"5.02","item_title":"Departure of Directors or Certain Officers","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"James K. Saccaro, Chief Financial Officer, is resigning effective August 14, 2026, to pursue a role outside the medical technology industry. While the filing also discloses the appointment of George Newcomb as interim CFO, the principal disclosed action centers on Saccaro's departure—a named executive officer leaving his position after three years. The CFO role is material to investor assessment of the company's financial leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:21:40.171515+00:00","company_name":"GE HealthCare Technologies Inc.","ticker":"GEHC","filing_date":"2026-07-23"}]}